5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α-glucosidase and urease enzymes

Tanzila Arshad, Khalid Mohammed Khan, Najma Rasool, Uzma Salar, Shafqat Hussain, Humna Asghar, Mohammed Ashraf, Abdul Wadood, Muhammad Riaz, Shahnaz Perveen, Muhammad Taha, Nor Hadiani Ismail

Research output: Research - peer-reviewArticle

  • 4 Citations

Abstract

On the basis of previous report on promising α-glucosidase inhibitory activity of 5-bromo-2-aryl benzimidazole derivatives, these derivatives were further screened for urease inhibitory and cytotoxicity activity in order to get more potent and non-cytotoxic potential dual inhibitor for the patients suffering from diabetes as well as peptic ulcer. In this study, all compounds showed varying degree of potency in the range of (IC50 = 8.15 ± 0.03–354.67 ± 0.19 μM) as compared to standard thiourea (IC50 = 21.25 ± 0.15 μM). It is worth mentioning that derivatives 7 (IC50 = 12.07 ± 0.05 μM), 8 (IC50 = 10.57 ± 0.12 μM), 11 (IC50 = 13.76 ± 0.02 μM), 14 (IC50 = 15.70 ± 0.12 μM) and 22 (IC50 = 8.15 ± 0.03 μM) were found to be more potent inhibitors than standard. All compounds were also evaluated for cytotoxicity towards 3T3 mouse fibroblast cell line and found to be completely non-toxic. Previously benzimidazole 1–25 were also showed α-glucosidase inhibitory potential. In silico studies were performed on the lead molecules i.e. 2, 7, 8, 11, 14, and 22, in order to rationalize the binding interaction of compounds with the active site of urease enzyme.

LanguageEnglish
Pages21-31
Number of pages11
JournalBioorganic Chemistry
Volume72
DOIs
StatePublished - Jun 1 2017

Fingerprint

Urease
Derivatives
Enzymes
Glycoside Hydrolase Inhibitors
benzimidazole
alpha-Glucosidases
Cytotoxicity
Thiourea
Peptic Ulcer
Computer Simulation
Catalytic Domain
Fibroblasts
Cell Line
Medical problems
Cells
Molecules

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Organic Chemistry

Cite this

5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α-glucosidase and urease enzymes. / Arshad, Tanzila; Khan, Khalid Mohammed; Rasool, Najma; Salar, Uzma; Hussain, Shafqat; Asghar, Humna; Ashraf, Mohammed; Wadood, Abdul; Riaz, Muhammad; Perveen, Shahnaz; Taha, Muhammad; Ismail, Nor Hadiani.

In: Bioorganic Chemistry, Vol. 72, 01.06.2017, p. 21-31.

Research output: Research - peer-reviewArticle

Arshad, T, Khan, KM, Rasool, N, Salar, U, Hussain, S, Asghar, H, Ashraf, M, Wadood, A, Riaz, M, Perveen, S, Taha, M & Ismail, NH 2017, '5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α-glucosidase and urease enzymes' Bioorganic Chemistry, vol 72, pp. 21-31. DOI: 10.1016/j.bioorg.2017.03.007
Arshad, Tanzila ; Khan, Khalid Mohammed ; Rasool, Najma ; Salar, Uzma ; Hussain, Shafqat ; Asghar, Humna ; Ashraf, Mohammed ; Wadood, Abdul ; Riaz, Muhammad ; Perveen, Shahnaz ; Taha, Muhammad ; Ismail, Nor Hadiani. / 5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α-glucosidase and urease enzymes. In: Bioorganic Chemistry. 2017 ; Vol. 72. pp. 21-31
@article{cffdcf213d674b44ad987a87856f6897,
title = "5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α-glucosidase and urease enzymes",
abstract = "On the basis of previous report on promising α-glucosidase inhibitory activity of 5-bromo-2-aryl benzimidazole derivatives, these derivatives were further screened for urease inhibitory and cytotoxicity activity in order to get more potent and non-cytotoxic potential dual inhibitor for the patients suffering from diabetes as well as peptic ulcer. In this study, all compounds showed varying degree of potency in the range of (IC50 = 8.15 ± 0.03–354.67 ± 0.19 μM) as compared to standard thiourea (IC50 = 21.25 ± 0.15 μM). It is worth mentioning that derivatives 7 (IC50 = 12.07 ± 0.05 μM), 8 (IC50 = 10.57 ± 0.12 μM), 11 (IC50 = 13.76 ± 0.02 μM), 14 (IC50 = 15.70 ± 0.12 μM) and 22 (IC50 = 8.15 ± 0.03 μM) were found to be more potent inhibitors than standard. All compounds were also evaluated for cytotoxicity towards 3T3 mouse fibroblast cell line and found to be completely non-toxic. Previously benzimidazole 1–25 were also showed α-glucosidase inhibitory potential. In silico studies were performed on the lead molecules i.e. 2, 7, 8, 11, 14, and 22, in order to rationalize the binding interaction of compounds with the active site of urease enzyme.",
author = "Tanzila Arshad and Khan, {Khalid Mohammed} and Najma Rasool and Uzma Salar and Shafqat Hussain and Humna Asghar and Mohammed Ashraf and Abdul Wadood and Muhammad Riaz and Shahnaz Perveen and Muhammad Taha and Ismail, {Nor Hadiani}",
year = "2017",
month = "6",
doi = "10.1016/j.bioorg.2017.03.007",
volume = "72",
pages = "21--31",
journal = "Bioorganic Chemistry",
issn = "0045-2068",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - 5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α-glucosidase and urease enzymes

AU - Arshad,Tanzila

AU - Khan,Khalid Mohammed

AU - Rasool,Najma

AU - Salar,Uzma

AU - Hussain,Shafqat

AU - Asghar,Humna

AU - Ashraf,Mohammed

AU - Wadood,Abdul

AU - Riaz,Muhammad

AU - Perveen,Shahnaz

AU - Taha,Muhammad

AU - Ismail,Nor Hadiani

PY - 2017/6/1

Y1 - 2017/6/1

N2 - On the basis of previous report on promising α-glucosidase inhibitory activity of 5-bromo-2-aryl benzimidazole derivatives, these derivatives were further screened for urease inhibitory and cytotoxicity activity in order to get more potent and non-cytotoxic potential dual inhibitor for the patients suffering from diabetes as well as peptic ulcer. In this study, all compounds showed varying degree of potency in the range of (IC50 = 8.15 ± 0.03–354.67 ± 0.19 μM) as compared to standard thiourea (IC50 = 21.25 ± 0.15 μM). It is worth mentioning that derivatives 7 (IC50 = 12.07 ± 0.05 μM), 8 (IC50 = 10.57 ± 0.12 μM), 11 (IC50 = 13.76 ± 0.02 μM), 14 (IC50 = 15.70 ± 0.12 μM) and 22 (IC50 = 8.15 ± 0.03 μM) were found to be more potent inhibitors than standard. All compounds were also evaluated for cytotoxicity towards 3T3 mouse fibroblast cell line and found to be completely non-toxic. Previously benzimidazole 1–25 were also showed α-glucosidase inhibitory potential. In silico studies were performed on the lead molecules i.e. 2, 7, 8, 11, 14, and 22, in order to rationalize the binding interaction of compounds with the active site of urease enzyme.

AB - On the basis of previous report on promising α-glucosidase inhibitory activity of 5-bromo-2-aryl benzimidazole derivatives, these derivatives were further screened for urease inhibitory and cytotoxicity activity in order to get more potent and non-cytotoxic potential dual inhibitor for the patients suffering from diabetes as well as peptic ulcer. In this study, all compounds showed varying degree of potency in the range of (IC50 = 8.15 ± 0.03–354.67 ± 0.19 μM) as compared to standard thiourea (IC50 = 21.25 ± 0.15 μM). It is worth mentioning that derivatives 7 (IC50 = 12.07 ± 0.05 μM), 8 (IC50 = 10.57 ± 0.12 μM), 11 (IC50 = 13.76 ± 0.02 μM), 14 (IC50 = 15.70 ± 0.12 μM) and 22 (IC50 = 8.15 ± 0.03 μM) were found to be more potent inhibitors than standard. All compounds were also evaluated for cytotoxicity towards 3T3 mouse fibroblast cell line and found to be completely non-toxic. Previously benzimidazole 1–25 were also showed α-glucosidase inhibitory potential. In silico studies were performed on the lead molecules i.e. 2, 7, 8, 11, 14, and 22, in order to rationalize the binding interaction of compounds with the active site of urease enzyme.

UR - http://www.scopus.com/inward/record.url?scp=85016039331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016039331&partnerID=8YFLogxK

U2 - 10.1016/j.bioorg.2017.03.007

DO - 10.1016/j.bioorg.2017.03.007

M3 - Article

VL - 72

SP - 21

EP - 31

JO - Bioorganic Chemistry

T2 - Bioorganic Chemistry

JF - Bioorganic Chemistry

SN - 0045-2068

ER -